AR
FPRX

Advisory Research’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Advisory Research’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-27,281
Closed -$1.37M – 429
2016
Q4 		$1.37M Buy
+27,281
New +$1.43M 0.02% 248

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Advisory Research's FPRX Position: Q1 2017 in Review

Advisory Research sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2017, closing a stake of 27,281 shares — an estimated $1.37M sold.

Advisory Research first reported a position in FPRX in Q4 2016 and held it in 1 quarter. The position peaked at $1.37M in Q4 2016. 157 funds tracked by Wall St. Rank hold FPRX as of Q1 2017.

  • Advisory Research reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Advisory Research sold 27,281 Five Prime Therapeutics, Inc. shares in Q1 2017, an estimated $1.37M.
  • Advisory Research first reported a position in Five Prime Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
  • Advisory Research's Five Prime Therapeutics, Inc. position peaked at $1.37M in Q4 2016.
  • 157 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2017.

Based on Advisory Research's 13F filing for Q1 2017, filed 15 May 2017.